The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s thrombophilia market report forecasts the thrombophilia market size to grow to $20.87 Billion by 2027, with a CAGR (compound annual growth rate) of 7%.

Learn More On The Thrombophilia Market Report 2023 – https://www.thebusinessresearchcompany.com/report/thrombophilia-global-market-report

Thrombophilia Market Size Forecast
The global thrombophilia market is expected to grow from $14.79 billion in 2022 to $15.90 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global thrombophilia market size is expected to grow to $20.87 billion in 2027 at a CAGR of 7.0%.

North America held the largest thrombophilia market share.

Key Thrombophilia Market Driver ­– Increase In The Elderly Population
According to data given by America’s Health Rankings, a US-based organisation that studies health outcomes, more than 56 million persons aged 65 and older will account for around 16.9% of the total US population in 2022. More than 73.1 million elderly individuals are predicted by 2030, when the baby boomer generation retires. As a result, the growing senior population is propelling the thrombophilia industry forward.

Request for A Sample Of The Global Thrombophilia Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9439&type=smp

Key Thrombophilia Market Trend – Technological Advancement
To maintain their market position, major market participants are inventing novel technology. For example, in 2021, the University of Oslo, a public research university in Norway, developed a brand-new technology known as super albumin, which could lead to the development of long-acting drugs and have significant implications for people suffering from haemophilia, a condition that impairs the blood’s ability to clot. The university’s research team created a cutting-edge biomedical approach that can be used to create coagulation factors with considerably longer half-lives than those now available. The examination of a biological mechanism is the starting step. Using the knowledge gathered from this research, they were able to create super albumin, a protein variation that can be combined with protein-based medications to increase their bloodstream half-life.

Thrombophilia Market Segment
1) By Type: Factor V Leiden, Prothrombin 20210, Antiphospholipid Syndrome, Other Type
2) By Drugs: Heparin, Warfarin, Other Drugs
3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration
4) By End-Users: Hospitals, Homecare, Speciality Centres, Other End Users

Thrombophilia Market Major Players and Strategies
Major players in the thrombophilia market are Pfizer Inc., F. Hoffmann-La Roche Limited, Mylan N.V., Changzhaou Qianhong Bio-pharma Co. Limited, Fresenius Kabi AG, Hebei Changshan Biochemical Pharmaceutical Co. Limited, Hikma Pharmaceuticals PLC., Novartis AG, Shanghai Fosun Pharmaceutical (Group) Co. Ltd., Shenzhen Hepalink Pharmaceutical Group Co. Limited, Teva Pharmaceutical Industries Limited, Yino Pharma Limited, Aspen Insurance Holdings Limited, Sanofi SA, and Eisai Co. Limited.

Arena Pharmaceuticals was acquired for $6.7 billion by Pfizer Inc., a US-based pharmaceutical business, in March 2022. Arena Pharmaceuticals becomes a part of Pfizer as a result of this transaction, and it will help generate innovations to better the lives of people suffering from immuno-inflammatory conditions. Arena Pharmaceuticals, Inc. is a company established in the United States that specialises in the treatment of thromboembolic illnesses of the arterial blood vessels.

The Thrombophilia Global Market Report 2023 covers regional data on thrombophilia market size, thrombophilia market trends and drivers, opportunities, strategies, and thrombophilia market competitor analysis. The countries covered in the thrombophilia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Thrombophilia is a blood condition that raises the likelihood of blood clotting in the veins and arteries. Blood clotting in arteries and veins can cause it, as can an inherited (genetic) or acquired tendency. It can lead to a heart attack, stroke, kidney failure, and pulmonary embolism.

View More Reports Related To The Thrombophilia Market –
Biosimilars Global Market Report 2023
Anemia And Other Blood Disorder Drugs Global Market Report 2023
Biosimilar Growth Hormones Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: